Esophageal submucosal dissection under steady pressure automatically controlled endoscopy (SPACE): A clinical feasibility study

Motohiko Kato, Kiyokazu Nakajima, Takuya Yamada, Masashi Hirota, Yasuaki Miyazaki, Makoto Yamasaki, Tsutomu Nishida, Masaki Mori, Yuichiro Doki, Masahiko Tsujii, Tetsuo Takehara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background and study aims: Steady pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434.

Original languageEnglish
Pages (from-to)680-684
Number of pages5
JournalEndoscopy
Volume46
Issue number8
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Feasibility Studies
Endoscopy
Dissection
Pressure
Insufflation
Carbon Dioxide
Safety
Clinical Trials, Phase I
Vital Signs
Partial Pressure
Endoscopic Mucosal Resection
Clinical Studies
Clinical Trials

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Esophageal submucosal dissection under steady pressure automatically controlled endoscopy (SPACE) : A clinical feasibility study. / Kato, Motohiko; Nakajima, Kiyokazu; Yamada, Takuya; Hirota, Masashi; Miyazaki, Yasuaki; Yamasaki, Makoto; Nishida, Tsutomu; Mori, Masaki; Doki, Yuichiro; Tsujii, Masahiko; Takehara, Tetsuo.

In: Endoscopy, Vol. 46, No. 8, 01.01.2014, p. 680-684.

Research output: Contribution to journalArticle

Kato, M, Nakajima, K, Yamada, T, Hirota, M, Miyazaki, Y, Yamasaki, M, Nishida, T, Mori, M, Doki, Y, Tsujii, M & Takehara, T 2014, 'Esophageal submucosal dissection under steady pressure automatically controlled endoscopy (SPACE): A clinical feasibility study', Endoscopy, vol. 46, no. 8, pp. 680-684. https://doi.org/10.1055/s-0034-1365465
Kato, Motohiko ; Nakajima, Kiyokazu ; Yamada, Takuya ; Hirota, Masashi ; Miyazaki, Yasuaki ; Yamasaki, Makoto ; Nishida, Tsutomu ; Mori, Masaki ; Doki, Yuichiro ; Tsujii, Masahiko ; Takehara, Tetsuo. / Esophageal submucosal dissection under steady pressure automatically controlled endoscopy (SPACE) : A clinical feasibility study. In: Endoscopy. 2014 ; Vol. 46, No. 8. pp. 680-684.
@article{5600bb311e9d4ac29894787d03328c59,
title = "Esophageal submucosal dissection under steady pressure automatically controlled endoscopy (SPACE): A clinical feasibility study",
abstract = "Background and study aims: Steady pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434.",
author = "Motohiko Kato and Kiyokazu Nakajima and Takuya Yamada and Masashi Hirota and Yasuaki Miyazaki and Makoto Yamasaki and Tsutomu Nishida and Masaki Mori and Yuichiro Doki and Masahiko Tsujii and Tetsuo Takehara",
year = "2014",
month = "1",
day = "1",
doi = "10.1055/s-0034-1365465",
language = "English",
volume = "46",
pages = "680--684",
journal = "Endoscopy",
issn = "0013-726X",
publisher = "Georg Thieme Verlag",
number = "8",

}

TY - JOUR

T1 - Esophageal submucosal dissection under steady pressure automatically controlled endoscopy (SPACE)

T2 - A clinical feasibility study

AU - Kato, Motohiko

AU - Nakajima, Kiyokazu

AU - Yamada, Takuya

AU - Hirota, Masashi

AU - Miyazaki, Yasuaki

AU - Yamasaki, Makoto

AU - Nishida, Tsutomu

AU - Mori, Masaki

AU - Doki, Yuichiro

AU - Tsujii, Masahiko

AU - Takehara, Tetsuo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background and study aims: Steady pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434.

AB - Background and study aims: Steady pressure automatically controlled endoscopy (SPACE) is a new insufflation system that provides constant carbon dioxide (CO2) insufflation pressure during prolonged procedures. The system consists of an overtube, a surgical insufflator, and a newly developed leak-proof valve. The aims of this study were to validate the feasibility and safety of SPACE for esophageal endoscopic submucosal dissection (ESD). Patients and methods: This was a clinical phase I trial, involving 10 patients who underwent esophageal ESD. The primary end point was the rate of adverse events within 30 days (grade 0 to 4). Secondary end points were changes in partial pressure of carbon dioxide (PaCO2) and vital signs during ESD, completion rate of ESD, and degree of abdominal distension by patient assessment and radiographic grading. Results: All adverse events were Grade 2 or less. Mild PaCO2elevation after ESD was noted; however, no associated symptoms were reported. The procedure was completed under SPACE alone in 8 of 10 patients. Minimal post-procedural bowel distension was observed. Conclusions: In this small pilot study, SPACE was feasible and appeared to be safe. Further study with larger case numbers is required to demonstrate efficacy and safety. Clinical trial registration: UMIN000005434.

UR - http://www.scopus.com/inward/record.url?scp=84904957729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904957729&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1365465

DO - 10.1055/s-0034-1365465

M3 - Article

C2 - 24770965

AN - SCOPUS:84904957729

VL - 46

SP - 680

EP - 684

JO - Endoscopy

JF - Endoscopy

SN - 0013-726X

IS - 8

ER -